DPX-formulated Products
Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 1Active
Key Facts
About BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |
| Alpha1H | Hamlet Biopharma | Phase 2 |
| LiPax | LIPAC Oncology | Phase 2 |
| VAX014 | Vaxiion Therapeutics | Phase 1/2 |
| ZH9 | Prokarium | Phase 1 |
| Dabogratinib (Onc) | Tyra Biosciences | Phase 1/2 |
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| VDC Platform | Aura Biosciences | Preclinical |